FDA Grants De Novo Marketing Authorization for Aletta Robotic Blood-Draw Device
The U.S. Food and Drug Administration (FDA) has granted marketing authorization for the Aletta robotic blood-draw device on August 19, 2026. This clearance was issued through the De Novo pathway, establishing the device as a pioneering technology authorized for clinical application. The FDA's decision involved a thorough assessment of the device's ...
- Published date: 17-09-2026 10:02 AM
On August 19, 2026, the U.S. Food and Drug Administration (FDA) announced the grant of marketing authorization for the Aletta robotic blood-draw device developed by Vitestro.
The device received clearance through the De Novo pathway, marking it as a first-of-its-kind technology authorized for clinical use.
This decision reflects the FDA's evaluation of the device's intended use, supporting its safety and efficacy for blood collection procedures.
The authorization represents a significant advancement in automated venipuncture technology, potentially improving patient care and clinical workflows.